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Abstract
Background: Pancreatic fistula is a potentially life-threatening complication after a pancreatic resec-
tion. The aim of this systematic review was to evaluate the role of matrix-bound sealants after a pan-
creatic resection in terms of preventing or ameliorating the course of a post-operative pancreatic
fistula.
Methods: A systematic search was performed in the literature from May 2005 to April 2015. Included
were clinical studies using matrix-bound sealants after a pancreatic resection, reporting a post-opera-
tive pancreatic fistula (POPF) according to the International Study Group on Pancreatic Fistula classifi-
cation, in which grade B and C fistulae were considered clinically relevant.
Results: Two were studies on patients undergoing pancreatoduodenectomy (sealants n = 67, controls
n = 27) and four studies on a distal pancreatectomy (sealants n = 258, controls n = 178). After a pan-
creatoduodenectomy, 13% of patients treated with sealants versus 11% of patients without sealants
developed a POPF (P = 0.76), of which 4% versus 4% were clinically relevant (P = 0.87). After a distal
pancreatectomy, 42% of patients treated with sealants versus 52% of patients without sealants devel-
oped a POPF (P = 0.03). Of these, 9% versus 12% were clinically relevant (P = 0.19).
Conclusions: The present data do not support the routine use of matrix-bound sealants after a pan-
creatic resection, as there was no effect on clinically relevant POPF. Larger, well-designed studies are
needed to determine the efficacy of sealants in preventing POPF after a pancreatoduodenectomy.
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Introduction
A pancreatic fistula is a potentially life-threatening complica-
tion after a pancreatic resection as it is associated with intra-
abdominal abscesses, sepsis and major haemorrhage.1–5 Even
although over the past decades the outcome has improved
owing to better a surgical technique and centralization of pan-
creatic surgery,6 a post-operative pancreatic fistula (POPF) still
occurs in up to 28% of patients undergoing a pancreatic resec-
tion.7
In 2005, the International Study Group on Pancreatic Fistula
(ISGPF) defined POPF as an amylase level in any amount of
measurable drain fluid of at least three times the upper level of
normal serum amylase on or after the third post-operative day.
POPF is graded A, B or C, in which grade B and C are clini-
cally relevant, as they require a change in treatment strategy.8
This standardized definition has been widely used in the litera-
ture ever since.
Several strategies have been proposed to decrease the inci-
dence of POPF but only a few are potentially successful. This
includes pancreatogastric anastomosis,9–15 external drainage of
the pancreatic anastomosis,16 pre-operative administration of
pasireotide (Novartis Oncology, Basel, Switzerland)17. Never-
theless, even in the intervention arms of these successful stud-
ies the incidence of POPF was still as high as 10%, and further
improvements are, therefore, needed.
This study was presented at the 10th Congress of the E-AHPBA, 29-31
May 2013, Belgrade, Serbia; 45th Annual Meeting of the EPC, 26–28 June
2013, Zurich, Switzerland and 7th Dutch Society of Gastroenterology
(NVGE) Autumn Meeting, 20–21 March 2013, Veldhoven, Netherlands.
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Over the past years, various types of fibrin sealants have
found their way into surgical practice. Some studies suggest
that fibrin glue is effective in preventing POPF, whereas others
show no clinically relevant benefit.18 Because fibrin glue is a
liquid and may, therefore, be easily washed away, fibrin seal-
ants combined with a collagen patch could be useful in pre-
venting POPF. Fibrin sealants have been proven to be effective
in controlling bleeding in cardiovascular and liver surgery19
and show favourable results in anastomotic sealing after a pul-
monary lobectomy.20 The sealing capacity may also strengthen
the anastomosis thereby improving anastomotic healing and,
hence, may lead to a decrease in incidence and severity of
POPF. This beneficial effect might lead to a reduction in major
morbidity and even mortality after a pancreatic resection, with
subsequent improvement of the patient’s quality of life and a
reduction in health care costs.21
The aim of this systematic review was to evaluate the role of
matrix-bound sealants after a pancreatic resection in terms of
preventing or ameliorating the course of a post-operative
pancreatic fistula.
Methods
Study selection
A systematic search of the literature from May 2005 to April
2015 in PubMed, Embase and the Cochrane Library was per-
formed in adherence to the PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-Analyses) guidelines.22
The search was limited to this interval because the first uni-
form ISGPF definitions for POPF were published in May
2005.8
PubMed, Embase and Cochrane Library search terms were:
‘(sealant OR sealing OR TachoSil OR TachoComb OR patch)
AND (pancreatoduodenectomy OR pancreaticoduodenectomy
OR PPPD OR Whipple OR pancreatic)’. All titles and abstracts
were screened. Full-text papers were reviewed by two authors
before inclusion. Reference lists were crosschecked for poten-
tially relevant studies.
Eligibility criteria
Included were all clinical studies written in English reporting
on the use of fibrin-sealant patches after a pancreatic resection.
Excluded were studies using sealants in a liquid form (i.e.
glue), studies not reporting a fistula or mortality, studies not
using the ISGPF definition on POPF and animal studies. When
multiple papers were identified from one group, it was checked
whether the study population overlapped. If so, the study with
the largest number of patients was included.
Assessment of methodological quality
All studies were graded for methodological quality. Random-
ized controlled trials were graded according to the Cochrane
Collaboration’s tool and 23 cohort studies in accordance to the
Newcastle-Ottawa quality assessment scale (NOS).24
Data extraction
The following data were extracted from the individual stud-
ies: study design, patient characteristics, the number of
patients undergoing a pancreatic resection, specifics on the
used sealant patch, the incidence and severity of POPF and
30-day mortality. When available, data on underlying disease,
performed procedure, the use of an internal or an external
stent in the pancreatic duct, post-operative abdominal drain,
the type of anastomosis, additional pharmacological therapy,
the incidence and severity of a post-pancreatectomy haemor-
rhage and delayed gastric emptying, the time to abdominal
drain removal, total morbidity and length of hospital stay,
and follow-up were also collected. Corresponding authors of
studies were contacted if any of these data were not
reported.
Statistical analysis
The primary outcomes were incidence and grade of POPF.
Patients treated with fibrin sealants were compared to a con-
trol group, containing patients who were not treated with seal-
ants. Separate analyses were performed for patients
undergoing a pancreatoduodenectomy versus a distal pancrea-
tectomy. Dichotomous data were evaluated using the
chi-square test. For all continuous data, the mean [standard
deviation (SD)] and median (range) values were extracted or
obtained from authors when not available in the manuscripts.
Using the mean (SD) values, the weighted mean (SD) values
were calculated, or calculated from median (range) values,
using the method reported by Hozo et al.25 A 2-sided P-value
of < 0.05 was considered statistically significant. Statistical
analyses were performed in SPSS version 20.0 (SPSS, Chicago,
IL, USA).
Results
The literature search identified 1132 papers for initial screen-
ing. Most of these studies were excluded after title and abstract
screening. A total of 19 studies were screened on full text, 13
studies were excluded based on the reasons listed in Fig. 1.
Six studies were included in the present systematic review.
Two of these regarded patients undergoing a pancreatoduoden-
ectomy26,27 and four studies regarding a distal pancreatec-
tomy.28–31 In three studies, the use of fibrin sealant after a
pancreatic resection was compared with the same procedure
without using a fibrin patch.26,29,30 The remaining three studies
were non-comparative, using a fibrin patch in all
patients.27,28,31 Characteristics of all studies are summarized in
Table 1.
Methodological quality
Details of the assessment of methodological quality are sum-
marized in Table 2. Only one randomized, controlled trial
was included (Oxford level of evidence 1b).29 In this study,
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the participants or study personnel were not blinded for
intervention or outcome. All other studies were cohort stud-
ies, one was prospective26 and four studies were retrospec-
tive27,28,30,31 (all Oxford level of evidence 2b). All patients
were selected in a consecutive fashion from a fixed time
frame. One study did not report any data on baseline charac-
teristics.26 All studies used the ISGPF definition for POPF.
However, all studies but one29 did not report the measure-
ment of amylase levels regularly or according to a protocol,
causing a high risk of measurement bias. The follow-up was
poorly reported in included studies. In the randomized trial,
there was a statistically significant imbalance between study
groups with regard to sex and procedure with or without
splenectomy.29 Most studies did not report on risk factors
for POPF, such as texture of the pancreas, diameter of pan-
creatic duct or the use of somatostatin analogues. Overall,
many data used to measure methodological quality are not
reported in the included studies, causing an uncertain risk
of bias.
Patient characteristics
Out of the 6 studies included, 94 patients underwent a
pancreatoduodenectomy and 436 patients underwent a distal
pancreatectomy. The number of patients per study varied from
15 to 275. From the 94 pancreatoduodenectomies, 64 patients
(68%) received a fibrin patch to cover the pancreaticojejunos-
tomy. After a distal pancreatectomy, the staple- or suture line
on the pancreatic stump was covered with a sealant patch in
243 patients (55%). Only one study on a pancreatoduodenec-
tomy reported the age (67.9  8.4 years) of the included
patients.27 In the studies on a distal pancreatectomy, the
weighted mean age was 63  10.4 years in the sealants group
and 62  13.8 years in the control group. One study reported
the American Society of Anesthesiologist (ASA) class [median
2 (1–3) for both groups].30 The study performed by Montorsi
et al.29 reported a pancreatic duct diameter of ≥3 mm in 15
patients (12%) in the control group and 17 patients (12%) in
the sealants group (P = 0.69). In this study, the pancreas was
found to be firm in 16 patients (12%) in the control group
and 23 patients (16%) in the sealants group (P = 0.40). Owing
to the difference in definition on a soft pancreas, these data
were not pooled.
Pancreatoduodenectomy
Two studies on the use of fibrin patches in a pancreato-
duodenectomy were included. Both used external drainage of
the pancreatic duct in their pancreaticojejunostomy. The prod-
ucts applied were TachoSil26 and TachoComb (both Takeda
Pharmaceutical, Tokyo, Japan)27, which were placed around
the pancreatic anastomoses. In one study, patients received
PubMed n = 510
Embase n = 600
Cochrane Library n = 193
Additional records identified through 
other sources n = 6
Records after duplicates removed
n = 1132
Records screened
n = 1132
Records excluded
n = 1113
Full-text articles assessed
for eligibility
n = 19
Full-text articles excluded,
with reasons (n = 13): 
• No use fibrin patch 
(n = 4)
• No separate data 
sealants group (n = 4)
• No report of
ISGPF POPF (n = 2)
• Inappropriate study 
design (n = 3)
Studies included in
qualitative synthesis
n = 6
Figure 1 Flowchart of study selection in a systematic review
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additional Octreotide for 6 days post-operatively.26 Details of
the procedures are summarized in Table 1.
Table 3 shows the outcomes reported in the included stud-
ies. After a pancreatoduodenectomy, 9 out of 67 patients
(13%) treated with sealants and 3 of 27 patients (11%) who
did not receive sealants developed POPF (P = 0.76). These
were a grade A POPF in six (9%) and two patients (7%),
respectively, (P = 0.81) and three (4%) versus one (4%) were
clinically relevant POPF, respectively (P = 0.87). The incidence
of a post-pancreatectomy haemorrhage after a pancreatoduo-
denectomy was only reported in one study: there were four
grade B post-pancreatectomy haemorrhages (15%) and no
Table 1 Characteristics of included studiesa
Study Country Study
design
Sample size
(control group)
(n)
Procedure Type of sealants
and application
Additional
therapy
Follow
-up
Chirletti26
(2009)
Italy Prospective
cohort
54 (27) Whipple TachoSil  placed around
pancreaticojejunostomy
Octreotide  6 days
postoperative
60 days
Mita27
(2011)
Japan Retrospective
cohort
40 Whipple (n = 21),
PPPD (n = 19)
Tachocomb  around
pancreaticojejunostomy,
1 min compression
No somatostatin
analogues
NR
Marangos30
(2011)
Norway Retrospective
cohort
121 (48) Laparoscopic distal
pancreatectomy
Tachosil  placed over
staple line
No somatostatin
analogues
NR
Mita28
(2011)
Japan Retrospective
cohort
25 Distal
pancreatectomy
Tachocomb  application
before transection
with stapler
No somatostatin
analogues
NR
Katagiri31
(2012)
Japan Retrospective
cohort
15 Laparoscopic distal
pancreatectomy
Tachocomb  over
staple line, 30 s
compression
NR NR
Montorsi29
(2012)
Italy Randomized
controlled
trial
275 Distal
pancreatectomy
Tachosil  over staple-
or suture line,
3 min compression
NR 2 months
aPPPD, pylorus preserving pancreatoduodenectomy; NR, not reported.
Table 2 Assessment of methodological quality
Study Oxford
level of
evidence
Newcastle – Ottawa quality
assessment Scale
The Cochrane Collaboration’s
tool for RCT’s
Selection bias Measurement
bias
Selection
bias
Performance
bias
Detection
bias
Attrition
bias
Reporting
bias
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26 2b ● ● ● ○ ● – – – – – –
27 2b ● – ● – ○ – – – – – –
30 2b ● ● ● ○ ○ – – – – – –
28 2b ● – ● – ○ – – – – – –
31 2b – ● – ○ – – – – – –
29 1b – – – – – – – ● ○ ● ●
●, Consistent with criteria, low risk of bias; , partly consistent with criteria, unknown risk of bias; ○, not consistent with criteria, high risk of bias;
–, not applicable.
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separate data were reported for the sealants and the control
groups.26 Total morbidity [n = 14 (35%)], the time to drain
removal (mean 9  4 days) and hospital stay (mean
33  9 days) after a pancreatoduodenectomy were only
reported in one study.27 Mortality after a pancreatoduodenec-
tomy was 2 out of 94 patients (2%, both in one study), one
from a myocardial infarction and one from sepsis owing to
pancreatitis.26
Distal pancreatectomy
In four studies patients underwent a distal pancreatectomy.28–31
In two studies, a distal pancreatectomy was performed laparo-
scopically,30,31 in one study all distal pancreatectomies were
open procedures28 and in one study both open and laparo-
scopic distal pancreatectomies were included.29 In most
patients, the pancreas was closed using a stapling device, only
in one study in some patients the pancreatic stump was hand
sewn.29 TachoSil (Takeda Pharmaceutical) was used in two
studies,29,30 TachoComb (Takeda Pharmaceutical) was the
product of use to cover the pancreatic stump in the two
remaining studies.28,31 In one study, the fibrin sealant was
firmly adhered to the pancreas before dividing it using a sta-
pler28 (Table 1).
Table 3 shows the outcomes. After a distal pancreatectomy,
there was a statistically significant decrease in POPF: 108 out
of 258 patients (42%) treated with sealants versus 93 out of
178 patients (52%) who did not receive fibrin sealants devel-
oped POPF (P = 0.03). These fistula were grade A in 86
patients in the sealants group (33%) versus 71 patients (40%)
in the control group (P = 0.16). There was no significant dif-
ference in clinically relevant fistula (grade B/C): 22 in the seal-
ants group (9%) versus 22 in the control group (12%) (P =
0.19). The incidence of a post-pancreatectomy haemorrhage
after a distal pancreatectomy was reported in two studies29,30:
four patients (2%) in the sealants group and seven patients
(4%) in the control group (P = 0.81). Data on delayed gastric
emptying were only reported in one study (0%).31 The number
of patients with one or more complications (total morbidity)
after a distal pancreatectomy was similar in both groups: 76
(35%) in the sealants group versus 64 (36%) in the control
group (P = 0.85). The mean duration of drainage (mean  SD)
was 7  13 days in the sealants group and 7  19 days in the
control group (data extracted from two studies28,29). One study
reported all drains were removed on post-operative day 1–4.31
The pooled mean duration of hospital stay (mean  SD) was
10  6 days in the sealants group and 9  7 days in the control
group. There was no mortality reported in the studies on a
distal pancreatectomy.
Discussion
The pooled data in this systematic review do not show an
advantage of the use of sealants after a pancreatic resection, as
there was no statistically significant decrease in the incidence
of clinically relevant fistula (i.e. ISGPF POPF grade B/C). With
regards to the other post-operative complications, time to
drain removal, hospital stay and mortality, no major differ-
ences between the sealants and control group were found.
Another recent study32(1996–2012) on the use of fibrin
sealants in patients undergoing a pancreatic resection evalu-
ated randomized, controlled trials investigating the use of all
types of fibrin sealants. The pooled data in this review also
showed no significant decrease in POPF using fibrin sealants.
This review did not select the studies based on the use of the
ISGPF definition. Before this definition was introduced in
2005, no uniform criteria for POPF were available. In con-
trast to the present study, this previous review included stud-
ies on liquid sealants as well as sealants combined with the
matrix. In the present review, only studies reporting on the
effect of matrix-bound sealants on POPF according to the IS-
GPF were included. Therefore, there was only one study
included in both the study by Orci et al. and the present
systematic review.29
Possibly, there is a different pathophysiology for the develop-
ment of POPF after a pancreatoduodenectomy versus a distal
pancreatectomy and, therefore, a different rationale for the use
of sealants. The inadequate healing of the pancreatic anastomo-
sis causes a fistula after a pancreatoduodenectomy, leading to
leakage of activated pancreatic juices into the abdominal cavity.
POPF after a distal pancreatectomy is the result of the failure of
the staple or suture line over the distal pancreatic duct. The
sphincter of Oddi is still functioning, preventing activation of
pancreatic juice. Once the closure of the distal pancreatic duct
fails, the fistula will be the way of lowest resistance when the
sphincter closes. For this reason, data on a pancreatoduodenec-
tomy and a distal pancreatectomy were presented separately.
Matrix-bound sealants might be used to seal the pancreatic
anastomosis after a pancreatoduodenectomy or to cover the clo-
sure line on the pancreatic stump after a distal pancreatectomy.
Liquid sealants are easily washed away and might not have this
sealing capacity. For this reason, only studies using fibrin sealant
combined with a collagen matrix, such as TachoSil or Tacho-
Comb (both Takeda Pharmaceutical) were included in this
review.
There were differences in the application of fibrin sealants in
studies included in this review. In one study, the fibrin patch
was adhered around the pancreas before it was transected using
a stapling device.28 Using this method, the cut surface of the
pancreas is not covered with the patch. This study included 25
patients undergoing a distal pancreatectomy with the addition
of a sealant patch. Of these, 5 patients (20%) developed POPF,
of which 1 was clinically relevant (grade B, 4%). The rate of
clinically relevant POPF was low in this study. Total morbidity
(28%) and time to drain removal (mean 8  2 days) was simi-
lar to other studies and previously published data on POPF
after a distal pancreatectomy.28–31 Hospital stay was somewhat
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long (mean 22  10 days), for which no explanation could be
extracted from the manuscript.
A limitation of this review is that most studies were of mod-
erate methodologic quality. Only one randomized, controlled
trial could be included and all other included studies were
observational cohort studies of which only one was prospec-
tively performed. These cohort studies had relatively small
sample sizes, especially the studies concerning a pancreatoduo-
denectomy. Also, the included studies were heterogeneous. A
pancreatojejunostomy was performed in all 94 patients under-
going a pancreatoduodenectomy. After a distal pancreatectomy
the pancreatic stump was either closed using staples or
sutures. The effect of matrix-bound sealants in a pancreato-
duodenectomy presented in this systematic review is based on
little evidence. Another important limitation of this study is
the lack of information reported on risk factors for POPF (e.g.
the texture of the pancreas, the diameter of the pancreatic duct
and the use of somatostatin analogues). Therefore, there could
be a significant difference in the distribution of these known
risk factors for POPF between the study groups. The effective-
ness of sealants in a distal pancreatectomy to prevent POPF
was unlikely, mostly owing to the results from the randomized,
controlled trial performed by Montorsi et al.
In conclusion, the present literature does not support the
routine use of sealants after a pancreatic resection because
there was no effect on a clinically relevant fistula. Larger well-
designed studies are needed to determine the efficacy of
matrix-bound sealants in preventing a pancreatic fistula after a
pancreatoduodenectomy.
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